This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Universal Health to Report Q2 Earnings: What Do the Key Estimates Say?
by Zacks Equity Research
UHS' Q2 results are likely to reflect gains from hospital and behavioral health services. However, rising costs may cloud earnings upside.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and Biotricity Inc. (BTCY) have performed compared to their sector so far this year.
ISRG Stock Gains on Q2 Earnings & Sales Beat, Gross Margin Contracts
by Zacks Equity Research
Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
by Zacks Equity Research
West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
by Zacks Equity Research
EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.
Labcorp Q2 Earnings Preview: Diagnostics Strength in Focus
by Zacks Equity Research
LH is likely to report Q2 growth with diagnostics momentum, key acquisitions, and new biomarker tests bolstering revenue gains.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
by Zacks Equity Research
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
TMO to Report Q2 Earnings: Analytical Instruments Segment in Focus
by Zacks Equity Research
Thermo Fisher eyes second-quarter 2025 growth with new tech launches in Analytical Instruments and Life-Science Solutions segments.
Should You Add Edwards Lifesciences Stock to Your Portfolio Now?
by Zacks Equity Research
EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.
Cardinal Health (CAH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Cardinal Health (CAH) stood at $159.46, denoting a -1.02% move from the preceding trading day.
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.
Should You Continue to Hold Veracyte Stock in Your Portfolio Now?
by Zacks Equity Research
VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ABT to Report Q2 Earnings: CGM and Cardiac Devices in Focus
by Zacks Equity Research
Abbott eyes Q2 growth with strong CGM momentum, cardiac device wins and resilient performance across key segments.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
Cardinal Health (CAH) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Cardinal Health (CAH) stood at $162.17, denoting a -1.27% move from the preceding trading day.
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
by Zacks Equity Research
STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
by Zacks Equity Research
TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
by Zacks Equity Research
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
Cardinal Health (CAH) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Cardinal Health (CAH) stood at $164.93, denoting a +1.82% move from the preceding trading day.
Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Cardinal Health (CAH) closed at $161.98, indicating a -1.47% shift from the previous trading day.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.